

ASX ANNOUNCEMENT

7 November 2018

Cynata Therapeutics Receives Notice of Allowance from European Patent Office for Cymerus™ Patent Application

Melbourne, Australia; 7 November 2018: Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, announced today that a Notice of Allowance has been received from the European Patent Office (EPO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell (MSC) technology. The patent application, entitled “Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions,” is owned by the University of Wisconsin–Madison’s Wisconsin Alumni Research Foundation (WARF) and is among the intellectual property licensed exclusively from WARF to Cynata.

“Our Cymerus therapeutic stem cell platform technology enables the economic production of commercial quantities of high-quality MSCs sourced from just one donor,” said Dr. Ross Macdonald, Cynata’s Chief Executive Officer. “The excellent efficacy and safety results of our Phase 1 clinical trial using Cymerus MSCs for the treatment of patients with steroid-resistant acute graft-versus-host disease validate the therapeutic potential of our proprietary platform. We look forward to continuing to strengthen our robust IP portfolio as we leverage Cymerus to advance the development of a new generation of MSC-based cell therapeutics in areas of high unmet medical need.”

The inventors named on the patent are Dr Gene Uenishi and Professor Igor Slukvin. Professor Slukvin is a founder, advisor and shareholder of Cynata.

The Notice of Allowance is sent to the applicant when the EPO intends to issue a patent. Cynata anticipates that the patent will be granted by late February 2019, with an expiration date of 12 March 2034.

Ends

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.com
Rosa Smith, Australia Media Contact, +61 (0) 475 305 047, rosa.smith@mcpartners.com.au
Annie Starr, U.S. Media Contact, +1 973 768 2170, astarr@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale and without the limitation of multiple donors.



Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus™ MSCs into Phase 2 trials for GvHD and critical limb ischemia. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of asthma, critical limb ischemia, diabetic wounds, heart attack and cytokine release syndrome, a life-threatening condition stemming from cancer immunotherapy.